AU2023238523B2 - Crystalline salt form of a shp2 inhibitor - Google Patents

Crystalline salt form of a shp2 inhibitor

Info

Publication number
AU2023238523B2
AU2023238523B2 AU2023238523A AU2023238523A AU2023238523B2 AU 2023238523 B2 AU2023238523 B2 AU 2023238523B2 AU 2023238523 A AU2023238523 A AU 2023238523A AU 2023238523 A AU2023238523 A AU 2023238523A AU 2023238523 B2 AU2023238523 B2 AU 2023238523B2
Authority
AU
Australia
Prior art keywords
cancer
triazin
chloropyridin
thio
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2023238523A
Other languages
English (en)
Other versions
AU2023238523A1 (en
Inventor
Katie Keaton BROWN
Connor James COWDREY
Aaron Keith GOODWIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of AU2023238523A1 publication Critical patent/AU2023238523A1/en
Application granted granted Critical
Publication of AU2023238523B2 publication Critical patent/AU2023238523B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2023238523A 2022-03-23 2023-03-20 Crystalline salt form of a shp2 inhibitor Active AU2023238523B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263323005P 2022-03-23 2022-03-23
US63/323,005 2022-03-23
PCT/IB2023/052709 WO2023180898A1 (en) 2022-03-23 2023-03-20 Crystalline salt form of a shp2 inhibitor

Publications (2)

Publication Number Publication Date
AU2023238523A1 AU2023238523A1 (en) 2024-08-22
AU2023238523B2 true AU2023238523B2 (en) 2025-10-30

Family

ID=85724850

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023238523A Active AU2023238523B2 (en) 2022-03-23 2023-03-20 Crystalline salt form of a shp2 inhibitor

Country Status (11)

Country Link
US (1) US20250214966A1 (enExample)
EP (1) EP4496629A1 (enExample)
JP (1) JP2025509818A (enExample)
KR (1) KR20240163705A (enExample)
CN (1) CN119095836A (enExample)
AR (1) AR128847A1 (enExample)
AU (1) AU2023238523B2 (enExample)
CA (1) CA3256136A1 (enExample)
MX (1) MX2024011603A (enExample)
TW (1) TW202346282A (enExample)
WO (1) WO2023180898A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020201991A1 (en) * 2019-04-02 2020-10-08 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002880A (es) 2018-09-14 2021-06-04 Unilever Ip Holdings B V Evaluacion de la eficacia de composiciones cosmeticas que no se deben enjuagar para proteger la piel de los contaminantes.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020201991A1 (en) * 2019-04-02 2020-10-08 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors

Also Published As

Publication number Publication date
JP2025509818A (ja) 2025-04-11
TW202346282A (zh) 2023-12-01
WO2023180898A1 (en) 2023-09-28
US20250214966A1 (en) 2025-07-03
AR128847A1 (es) 2024-06-19
CA3256136A1 (en) 2023-09-28
CN119095836A (zh) 2024-12-06
KR20240163705A (ko) 2024-11-19
AU2023238523A1 (en) 2024-08-22
MX2024011603A (es) 2024-09-30
EP4496629A1 (en) 2025-01-29

Similar Documents

Publication Publication Date Title
TWI745831B (zh) Ｃｄｋ抑制劑之晶形
AU2017284702B2 (en) Pyrrolopyrimidine crystal for preparing JAK inhibitor
CN107667108B (zh) 作为jak激酶抑制剂的萘啶化合物
WO2021088945A1 (zh) 作为shp2抑制剂的化合物及其应用
US20240190843A1 (en) Crystalline form of a shp2 inhibitor
CN122003424A (zh) 一种稠环化合物及在kras抑制剂方面的应用
EP3476841A1 (en) Crystals of aniline pyrimidine compound serving as egfr inhibitor
CN118772176A (zh) 一种嘧啶并芳环化合物及其制备方法和用途
CN111032646A (zh) 作为jak激酶抑制剂的吡唑并和三唑并双环化合物
JP2018521076A (ja) Ｋｉｔ及びｐｄｇｆｒに関連する疾病を治療するのに有用な化合物
WO2017016463A1 (zh) Egfr抑制剂及其药学上可接受的盐和多晶型物及其应用
CN118632850A (zh) Apol1的螺环抑制剂和其使用方法
JP7554007B2 (ja) Ｊａｋ阻害剤化合物及びその使用
TW202124373A (zh) 1，3，5-三衍生物或其溶劑合物之結晶及其製造方法
KR102531772B1 (ko) Cdk4/6 키나아제 억제제를 타겟팅하는 결정형
US20250214966A1 (en) Crystalline Salt Form Of A SHP2 Inhibitor
CA3218470A1 (en) Polymorph of imidazolidinone compound, preparation method therefor and use thereof
HK40112682A (zh) Shp2抑制剂的结晶盐形式
US20230192710A1 (en) Jak inhibitor compound and use thereof
EP4570800A1 (en) Crystal form of pyridinopyrimidinone compound, acid salt thereof, crystal form of acid salt thereof, and use
CN108530450B (zh) 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用
CA3263285A1 (en) Crystal form of pyridinopyrimidinone compound, acid salt thereof, crystal form of acid salt thereof, and use
EA050379B1 (ru) Соль соединения на основе пирролопиримидина, его кристаллическая форма и их применение
TW202328152A (zh) 氮雜內醯胺化合物之晶型
CN112209933A (zh) 含有4-氮杂螺庚烷的btk抑制剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)